The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis
The relationship between metformin and prostate cancer (PCa) remains controversial. To clarify this association, the PubMed, Embase and Cochrane library databases were systematically searched from their inception dates to May 23, 2018, using the keywords “metformin” and “prostate cancer” to identify...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2019-02, Vol.9 (1), p.2218, Article 2218 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 2218 |
| container_title | Scientific reports |
| container_volume | 9 |
| creator | He, Kancheng Hu, Huating Ye, Senlin Wang, Haohui Cui, Rongrong Yi, Lu |
| description | The relationship between metformin and prostate cancer (PCa) remains controversial. To clarify this association, the PubMed, Embase and Cochrane library databases were systematically searched from their inception dates to May 23, 2018, using the keywords “metformin” and “prostate cancer” to identify the related studies. The results included incidence, overall survival (OS), PCa-specific survival (CSS) and recurrence-free survival (RFS), which were measured as hazard ratios (HR) with a 95% confidence interval (95% CI) using Review Manager 5.3 software. A total of 30 cohort studies, including 1,660,795 patients were included in this study. Our study revealed that metformin treatment improves OS, CSS and RFS in PCa (HR = 0.72, 95% CI: 0.59–0.88, P = 0.001; HR = 0.78, 95% CI: 0.64–0.94, P = 0.009; and HR = 0.60, 95% CI: 0.42–0.87 P = 0.006, respectively) compared with non-metformin treatment. However, metformin usage did not reduce the incidence of PCa (HR = 0.86, 95% CI: 0.55–1.34, P = 0.51). In conclusion, compared with non-metformin treatment, metformin therapy can significantly improve OS, CSS and RFS in PCa patients. No association was noted between metformin therapy and PCa incidence. This study indicates a useful direction for the clinical treatment of PCa. |
| doi_str_mv | 10.1038/s41598-018-38285-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6379374</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2183179284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c588t-c0dfc74b6caebaa693173f0e9bc7ac7dedd504210245d24fe2e93313284e09013</originalsourceid><addsrcrecordid>eNp9kc1vFCEYxonR2Kb2H_BgSLx4GeVrBvBg0jRqmzTxUs-EZV52aWZgBbab_e9LO7VWD3Lh4_09Dy88CL2l5CMlXH0qgvZadYSqjium-m7_Ah0zIvqOccZePlsfodNSbkgbPdOC6tfoiBMpFVH0GNXrDWDwHlzFyeMZqk95DhHXDWS7PeAUcYgujBAdYBtHvM1pHVMJpZ3fb0q1FbCzrZ4_4zNcDqXCbGtwOMNtgP2DqhnbzkY7HZryDXrl7VTg9HE-QT-_fb0-v-iufny_PD-76lyvVO0cGb2TYjU4CytrB82p5J6AXjlpnRxhHHsiGCVM9CMTHhhozilnSgDRhPIT9GXx3e5WM4wOYs12MtscZpsPJtlg_q7EsDHrdGsGLjWXohl8eDTI6dcOSjVzKA6myUZIu2IYVXzoyaB1Q9__g96kXW4PXigqdWurUWyhXPu4ksE_NUOJuc_VLLmalqt5yNXsm-jd82c8SX6n2AC-AKWV4hryn7v_Y3sHiOKw2g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2183179284</pqid></control><display><type>article</type><title>The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>He, Kancheng ; Hu, Huating ; Ye, Senlin ; Wang, Haohui ; Cui, Rongrong ; Yi, Lu</creator><creatorcontrib>He, Kancheng ; Hu, Huating ; Ye, Senlin ; Wang, Haohui ; Cui, Rongrong ; Yi, Lu</creatorcontrib><description>The relationship between metformin and prostate cancer (PCa) remains controversial. To clarify this association, the PubMed, Embase and Cochrane library databases were systematically searched from their inception dates to May 23, 2018, using the keywords “metformin” and “prostate cancer” to identify the related studies. The results included incidence, overall survival (OS), PCa-specific survival (CSS) and recurrence-free survival (RFS), which were measured as hazard ratios (HR) with a 95% confidence interval (95% CI) using Review Manager 5.3 software. A total of 30 cohort studies, including 1,660,795 patients were included in this study. Our study revealed that metformin treatment improves OS, CSS and RFS in PCa (HR = 0.72, 95% CI: 0.59–0.88, P = 0.001; HR = 0.78, 95% CI: 0.64–0.94, P = 0.009; and HR = 0.60, 95% CI: 0.42–0.87 P = 0.006, respectively) compared with non-metformin treatment. However, metformin usage did not reduce the incidence of PCa (HR = 0.86, 95% CI: 0.55–1.34, P = 0.51). In conclusion, compared with non-metformin treatment, metformin therapy can significantly improve OS, CSS and RFS in PCa patients. No association was noted between metformin therapy and PCa incidence. This study indicates a useful direction for the clinical treatment of PCa.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-018-38285-w</identifier><identifier>PMID: 30778081</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4025/1752 ; 692/499 ; Antidiabetics ; Disease Susceptibility ; Humanities and Social Sciences ; Humans ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Incidence ; Male ; Medical prognosis ; Meta-analysis ; Metformin ; Metformin - adverse effects ; Metformin - therapeutic use ; multidisciplinary ; Patients ; Prognosis ; Proportional Hazards Models ; Prostate cancer ; Prostatic Neoplasms - epidemiology ; Prostatic Neoplasms - etiology ; Prostatic Neoplasms - mortality ; Science ; Science (multidisciplinary) ; Survival ; Survival Analysis ; Systematic review</subject><ispartof>Scientific reports, 2019-02, Vol.9 (1), p.2218, Article 2218</ispartof><rights>The Author(s) 2019</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c588t-c0dfc74b6caebaa693173f0e9bc7ac7dedd504210245d24fe2e93313284e09013</citedby><cites>FETCH-LOGICAL-c588t-c0dfc74b6caebaa693173f0e9bc7ac7dedd504210245d24fe2e93313284e09013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379374/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379374/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30778081$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Kancheng</creatorcontrib><creatorcontrib>Hu, Huating</creatorcontrib><creatorcontrib>Ye, Senlin</creatorcontrib><creatorcontrib>Wang, Haohui</creatorcontrib><creatorcontrib>Cui, Rongrong</creatorcontrib><creatorcontrib>Yi, Lu</creatorcontrib><title>The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>The relationship between metformin and prostate cancer (PCa) remains controversial. To clarify this association, the PubMed, Embase and Cochrane library databases were systematically searched from their inception dates to May 23, 2018, using the keywords “metformin” and “prostate cancer” to identify the related studies. The results included incidence, overall survival (OS), PCa-specific survival (CSS) and recurrence-free survival (RFS), which were measured as hazard ratios (HR) with a 95% confidence interval (95% CI) using Review Manager 5.3 software. A total of 30 cohort studies, including 1,660,795 patients were included in this study. Our study revealed that metformin treatment improves OS, CSS and RFS in PCa (HR = 0.72, 95% CI: 0.59–0.88, P = 0.001; HR = 0.78, 95% CI: 0.64–0.94, P = 0.009; and HR = 0.60, 95% CI: 0.42–0.87 P = 0.006, respectively) compared with non-metformin treatment. However, metformin usage did not reduce the incidence of PCa (HR = 0.86, 95% CI: 0.55–1.34, P = 0.51). In conclusion, compared with non-metformin treatment, metformin therapy can significantly improve OS, CSS and RFS in PCa patients. No association was noted between metformin therapy and PCa incidence. This study indicates a useful direction for the clinical treatment of PCa.</description><subject>692/4025/1752</subject><subject>692/499</subject><subject>Antidiabetics</subject><subject>Disease Susceptibility</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Metformin</subject><subject>Metformin - adverse effects</subject><subject>Metformin - therapeutic use</subject><subject>multidisciplinary</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - epidemiology</subject><subject>Prostatic Neoplasms - etiology</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Systematic review</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1vFCEYxonR2Kb2H_BgSLx4GeVrBvBg0jRqmzTxUs-EZV52aWZgBbab_e9LO7VWD3Lh4_09Dy88CL2l5CMlXH0qgvZadYSqjium-m7_Ah0zIvqOccZePlsfodNSbkgbPdOC6tfoiBMpFVH0GNXrDWDwHlzFyeMZqk95DhHXDWS7PeAUcYgujBAdYBtHvM1pHVMJpZ3fb0q1FbCzrZ4_4zNcDqXCbGtwOMNtgP2DqhnbzkY7HZryDXrl7VTg9HE-QT-_fb0-v-iufny_PD-76lyvVO0cGb2TYjU4CytrB82p5J6AXjlpnRxhHHsiGCVM9CMTHhhozilnSgDRhPIT9GXx3e5WM4wOYs12MtscZpsPJtlg_q7EsDHrdGsGLjWXohl8eDTI6dcOSjVzKA6myUZIu2IYVXzoyaB1Q9__g96kXW4PXigqdWurUWyhXPu4ksE_NUOJuc_VLLmalqt5yNXsm-jd82c8SX6n2AC-AKWV4hryn7v_Y3sHiOKw2g</recordid><startdate>20190218</startdate><enddate>20190218</enddate><creator>He, Kancheng</creator><creator>Hu, Huating</creator><creator>Ye, Senlin</creator><creator>Wang, Haohui</creator><creator>Cui, Rongrong</creator><creator>Yi, Lu</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190218</creationdate><title>The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis</title><author>He, Kancheng ; Hu, Huating ; Ye, Senlin ; Wang, Haohui ; Cui, Rongrong ; Yi, Lu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c588t-c0dfc74b6caebaa693173f0e9bc7ac7dedd504210245d24fe2e93313284e09013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>692/4025/1752</topic><topic>692/499</topic><topic>Antidiabetics</topic><topic>Disease Susceptibility</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Metformin</topic><topic>Metformin - adverse effects</topic><topic>Metformin - therapeutic use</topic><topic>multidisciplinary</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - epidemiology</topic><topic>Prostatic Neoplasms - etiology</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Kancheng</creatorcontrib><creatorcontrib>Hu, Huating</creatorcontrib><creatorcontrib>Ye, Senlin</creatorcontrib><creatorcontrib>Wang, Haohui</creatorcontrib><creatorcontrib>Cui, Rongrong</creatorcontrib><creatorcontrib>Yi, Lu</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Kancheng</au><au>Hu, Huating</au><au>Ye, Senlin</au><au>Wang, Haohui</au><au>Cui, Rongrong</au><au>Yi, Lu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2019-02-18</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>2218</spage><pages>2218-</pages><artnum>2218</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>The relationship between metformin and prostate cancer (PCa) remains controversial. To clarify this association, the PubMed, Embase and Cochrane library databases were systematically searched from their inception dates to May 23, 2018, using the keywords “metformin” and “prostate cancer” to identify the related studies. The results included incidence, overall survival (OS), PCa-specific survival (CSS) and recurrence-free survival (RFS), which were measured as hazard ratios (HR) with a 95% confidence interval (95% CI) using Review Manager 5.3 software. A total of 30 cohort studies, including 1,660,795 patients were included in this study. Our study revealed that metformin treatment improves OS, CSS and RFS in PCa (HR = 0.72, 95% CI: 0.59–0.88, P = 0.001; HR = 0.78, 95% CI: 0.64–0.94, P = 0.009; and HR = 0.60, 95% CI: 0.42–0.87 P = 0.006, respectively) compared with non-metformin treatment. However, metformin usage did not reduce the incidence of PCa (HR = 0.86, 95% CI: 0.55–1.34, P = 0.51). In conclusion, compared with non-metformin treatment, metformin therapy can significantly improve OS, CSS and RFS in PCa patients. No association was noted between metformin therapy and PCa incidence. This study indicates a useful direction for the clinical treatment of PCa.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30778081</pmid><doi>10.1038/s41598-018-38285-w</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2019-02, Vol.9 (1), p.2218, Article 2218 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6379374 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature OA Free Journals; Nature Free; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | 692/4025/1752 692/499 Antidiabetics Disease Susceptibility Humanities and Social Sciences Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Incidence Male Medical prognosis Meta-analysis Metformin Metformin - adverse effects Metformin - therapeutic use multidisciplinary Patients Prognosis Proportional Hazards Models Prostate cancer Prostatic Neoplasms - epidemiology Prostatic Neoplasms - etiology Prostatic Neoplasms - mortality Science Science (multidisciplinary) Survival Survival Analysis Systematic review |
| title | The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A40%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20metformin%20therapy%20on%20incidence%20and%20prognosis%20in%20prostate%20cancer:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Scientific%20reports&rft.au=He,%20Kancheng&rft.date=2019-02-18&rft.volume=9&rft.issue=1&rft.spage=2218&rft.pages=2218-&rft.artnum=2218&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-018-38285-w&rft_dat=%3Cproquest_pubme%3E2183179284%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2183179284&rft_id=info:pmid/30778081&rfr_iscdi=true |